Liquidia (NASDAQ:LQDA) Director Stephen Bloch Sells 100,000 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $75.74, for a total transaction of $7,574,000.00. Following the transaction, the director directly owned 880,073 shares of the company’s stock, valued at approximately $66,656,729.02. This represents a 10.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Liquidia Stock Performance

NASDAQ LQDA opened at $75.54 on Thursday. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $77.09. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock has a market capitalization of $6.72 billion, a PE ratio of 539.61 and a beta of 0.58. The company’s 50 day simple moving average is $55.24 and its two-hundred day simple moving average is $43.20.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. Liquidia’s revenue was up 4187.1% on a year-over-year basis. Analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after buying an additional 16,022 shares in the last quarter. Creative Planning raised its holdings in shares of Liquidia by 40.7% during the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after buying an additional 7,765 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Liquidia by 13.4% in the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after buying an additional 11,111 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LQDA. BTIG Research upped their target price on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Oppenheimer set a $75.00 price objective on Liquidia in a report on Friday, June 5th. HC Wainwright upped their price objective on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, June 5th. Finally, Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.43.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).